bioAffinity Technologies, Inc. - רווח נקי למניה ב-12 החודשים האחרונים BIAF

bioAffinity Technologies (BIAF) is implementing the non-invasive CyPath Lung method for early-stage lung cancer detection. The 12-month YoY percentage change in EPS demonstrates growth driven by AI-powered cytometry robotics and steady diagnostic laboratory utilization. The current mark of 87.40 captures this metric, confirming the fundamental resilience of earnings per share.

Investors utilize this indicator to stress-test the resilience of earnings trends. bioAffinity Technologies (BIAF) is strengthening its position in lung cancer diagnostics through its unique sputum analysis platform. The annual shift in EPS TTM measures the percentage change in net income per share over a rolling year. This metric reflects the efficiency of monetizing the company's technological advantage and pricing power. The growing trend confirms the scalability of the business.